Synergism between alpha-interferon and interleukin-2-activated killer cells: In vitro studies

F. Di Raimondo, R. LaPushin, Evan M Hersh

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The effects of a combination of recombinant alpha-interferon (IFN-α) and interleukin-2 (IL-2)-activated human killer cells (lymphokine-activated killer or LAK cells) on Hs294T (IFN-sensitive) and A375P (IFN-resistant) human melanoma cell lines were evaluated. Pretreatment of target cells with IFN-α for at least 1 day increased their susceptibility to the lytic activity of LAK cells. The combination of the two agents in sequence (IFN-α followed by LAK cells) resulted in a true synergystic killing of both IFN-α-sensitive and -resistant tumor cells. No synergy was observed when the sequence was reversed (LAK cells followed by IFN-α). When peripheral blood mononuclear cells were incubated simultaneously with IFN-α and IL-2, LAK cell generation and antitumor activity was markedly inhibited when tested against both IFN-treated and -non-treated tumor cells. These studies may be used to plan clinical trials of combination cytokine therapy for human cancer.

Original languageEnglish (US)
Pages (from-to)77-83
Number of pages7
JournalActa Haematologica
Volume78
Issue numberSUPPL. 1
StatePublished - 1987
Externally publishedYes

Fingerprint

Lymphokine-Activated Killer Cells
Interferon-alpha
Interleukin-2
Neoplasms
In Vitro Techniques
Melanoma
Blood Cells
Clinical Trials
Cytokines
Cell Line

ASJC Scopus subject areas

  • Hematology

Cite this

Synergism between alpha-interferon and interleukin-2-activated killer cells : In vitro studies. / Di Raimondo, F.; LaPushin, R.; Hersh, Evan M.

In: Acta Haematologica, Vol. 78, No. SUPPL. 1, 1987, p. 77-83.

Research output: Contribution to journalArticle

@article{c9c4b17131ce46a6b47f970e54eb672f,
title = "Synergism between alpha-interferon and interleukin-2-activated killer cells: In vitro studies",
abstract = "The effects of a combination of recombinant alpha-interferon (IFN-α) and interleukin-2 (IL-2)-activated human killer cells (lymphokine-activated killer or LAK cells) on Hs294T (IFN-sensitive) and A375P (IFN-resistant) human melanoma cell lines were evaluated. Pretreatment of target cells with IFN-α for at least 1 day increased their susceptibility to the lytic activity of LAK cells. The combination of the two agents in sequence (IFN-α followed by LAK cells) resulted in a true synergystic killing of both IFN-α-sensitive and -resistant tumor cells. No synergy was observed when the sequence was reversed (LAK cells followed by IFN-α). When peripheral blood mononuclear cells were incubated simultaneously with IFN-α and IL-2, LAK cell generation and antitumor activity was markedly inhibited when tested against both IFN-treated and -non-treated tumor cells. These studies may be used to plan clinical trials of combination cytokine therapy for human cancer.",
author = "{Di Raimondo}, F. and R. LaPushin and Hersh, {Evan M}",
year = "1987",
language = "English (US)",
volume = "78",
pages = "77--83",
journal = "Acta Haematologica",
issn = "0001-5792",
publisher = "S. Karger AG",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Synergism between alpha-interferon and interleukin-2-activated killer cells

T2 - In vitro studies

AU - Di Raimondo, F.

AU - LaPushin, R.

AU - Hersh, Evan M

PY - 1987

Y1 - 1987

N2 - The effects of a combination of recombinant alpha-interferon (IFN-α) and interleukin-2 (IL-2)-activated human killer cells (lymphokine-activated killer or LAK cells) on Hs294T (IFN-sensitive) and A375P (IFN-resistant) human melanoma cell lines were evaluated. Pretreatment of target cells with IFN-α for at least 1 day increased their susceptibility to the lytic activity of LAK cells. The combination of the two agents in sequence (IFN-α followed by LAK cells) resulted in a true synergystic killing of both IFN-α-sensitive and -resistant tumor cells. No synergy was observed when the sequence was reversed (LAK cells followed by IFN-α). When peripheral blood mononuclear cells were incubated simultaneously with IFN-α and IL-2, LAK cell generation and antitumor activity was markedly inhibited when tested against both IFN-treated and -non-treated tumor cells. These studies may be used to plan clinical trials of combination cytokine therapy for human cancer.

AB - The effects of a combination of recombinant alpha-interferon (IFN-α) and interleukin-2 (IL-2)-activated human killer cells (lymphokine-activated killer or LAK cells) on Hs294T (IFN-sensitive) and A375P (IFN-resistant) human melanoma cell lines were evaluated. Pretreatment of target cells with IFN-α for at least 1 day increased their susceptibility to the lytic activity of LAK cells. The combination of the two agents in sequence (IFN-α followed by LAK cells) resulted in a true synergystic killing of both IFN-α-sensitive and -resistant tumor cells. No synergy was observed when the sequence was reversed (LAK cells followed by IFN-α). When peripheral blood mononuclear cells were incubated simultaneously with IFN-α and IL-2, LAK cell generation and antitumor activity was markedly inhibited when tested against both IFN-treated and -non-treated tumor cells. These studies may be used to plan clinical trials of combination cytokine therapy for human cancer.

UR - http://www.scopus.com/inward/record.url?scp=0023550341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023550341&partnerID=8YFLogxK

M3 - Article

C2 - 3124452

AN - SCOPUS:0023550341

VL - 78

SP - 77

EP - 83

JO - Acta Haematologica

JF - Acta Haematologica

SN - 0001-5792

IS - SUPPL. 1

ER -